Volume 143, Issue 4, Pages 986-994.e3 (October 2012) Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria  Christophe Duvoux, Françoise Roudot–Thoraval, Thomas Decaens, Fabienne Pessione, Hanaa Badran, Tullio Piardi, Claire Francoz, Philippe Compagnon, Claire Vanlemmens, Jérome Dumortier, Sébastien Dharancy, Jean Gugenheim, Pierre–Henri Bernard, René Adam, Sylvie Radenne, Fabrice Muscari, Filomena Conti, Jean Hardwigsen, Georges–Philippe Pageaux, Olivier Chazouillères, Ephrem Salame, Marie–Noelle Hilleret, Pascal Lebray, Armand Abergel, Marilyne Debette–Gratien, Michael D. Kluger, Ariane Mallat, Daniel Azoulay, Daniel Cherqui  Gastroenterology  Volume 143, Issue 4, Pages 986-994.e3 (October 2012) DOI: 10.1053/j.gastro.2012.05.052 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 Rates of (A) recurrence and (B) overall survival rates according to α-fetoprotein level in the training cohort. AFP ≤100 ng/L (solid line); AFP = 100–1000 ng/L (dashed line); AFP >1000 ng/L (dotted line). Gastroenterology 2012 143, 986-994.e3DOI: (10.1053/j.gastro.2012.05.052) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 Tumor recurrence (red) and survival rates (black) according to the AFP model in the (A) training cohort and in the (B) validation cohort ABM. Solid line for low-risk group, dashed line for high-risk group. Gastroenterology 2012 143, 986-994.e3DOI: (10.1053/j.gastro.2012.05.052) Copyright © 2012 AGA Institute Terms and Conditions

Figure 3 Tumor recurrence rates according to the AFP model in patients exceeding Milan criteria in the (A) training cohort and in the (B) validation cohort ABM, and in (C) patients within Milan criteria in the training cohort and in the (D) validation cohort ABM. Solid line for low-risk group, dashed line for high-risk group. Gastroenterology 2012 143, 986-994.e3DOI: (10.1053/j.gastro.2012.05.052) Copyright © 2012 AGA Institute Terms and Conditions

Figure 4 (A) Risk of post-transplant recurrence according to the AFP model evaluated on re-assessment during the waiting phase in 187 patients of the validation cohort, including 138 patients with bridging therapies. Solid line for low risk points and dashed line for high risk points. (B) Risk of post-transplant recurrence in the validation cohort according to changes in the AFP model over the waiting phase. LR-LR for points at low risk who remained at low risk; HR-HR for points at high risk who remained at high risk; LR-HR for points at low risk who became at high risk; and HR-LR for points at high risk who became at low risk. Gastroenterology 2012 143, 986-994.e3DOI: (10.1053/j.gastro.2012.05.052) Copyright © 2012 AGA Institute Terms and Conditions